Cheap malaria vaccine approved for global rollout. The vaccine could save millions of lives each year.

The R21 vaccine was developed by the University of Oxford, the Serum Institute of India, and drug maker Novavax. It is the first malaria vaccine to meet the WHO's target of 75% efficacy. The WHO has recommended R21 for widespread use in children aged 6 months to 17 years. The vaccine is expected to be available to countries in mid-2024. The approval of R21 is a major breakthrough in the fight against malaria. It is the first malaria vaccine to be recommended for widespread use by the WHO, and it is expected to save millions of lives.

Here are some additional details about the R21 vaccine: It is a two-dose vaccine that is given one month apart. It is safe and effective for children and adults. It is expected to be affordable and accessible to people in all parts of the world. The R21 vaccine is a major step forward in the fight against malaria. It is expected to save millions of lives and help to create a malaria-free world.